Context: Compensatory increases in fibroblast growth factor 23 (FGF23) with increasing phosphate intake may adversely impact health. However, population and clinical studies examining the link between phosphate intake and FGF23 levels have focused mainly on populations living in highly industrialized societies in which phosphate exposure may be homogenous.
A dequate phosphate intake is essential for bone health, but increasing phosphate intake may promote compensatory increases in fibroblast growth factor-23 (FGF23), a phosphaturic polypeptide (1) . In the setting of normal glomerular filtration rate (GFR), FGF23 holds serum phosphate levels within a normal range, regardless of phosphate intake via the down-regulation of sodium phosphate cotransporters in the proximal tubule, which inhibits phosphate reabsorption (1) . FGF23 also inhibits renal 1␣-hydroxylase activity and reduces conversion of 25-hydroxyvitamin D to the active form of vitamin D (1,25-dihydroxyvitamin D), which up-regulates gastrointestinal phosphate absorption (2) (3) (4) . Higher FGF23 levels are associated with a heightened risk of adverse cardiovascular outcomes (5, 6) . Thus, compensatory increases in FGF23 with increasing phosphate intake may adversely impact health (7) .
Population and clinical studies examining the link between phosphate intake and FGF23 levels have mainly focused on populations living in highly industrialized societies. The lack of consistent associations noted between phosphate intake and FGF23 levels (8 -13) may be a function of the ubiquitous exposure to phosphate additives, which may add up to 1000 mg/d of dietary phosphate intake (14, 15) . In addition, standard dietary measures poorly quantify dietary phosphate intake due to the hidden sources of inorganic phosphate in many foods (16, 17) . Contrasting urinary measures of phosphate excretion and FGF23 levels across populations that differ by level of economic transition provides a model to explore associations between sustained increases in phosphate intake and FGF23 levels. We have previously demonstrated that adults living in a rural area of Nigeria have significantly lower levels of net phosphate absorption, as reflected by higher urinary phosphate excretion, and lower FGF23 levels compared with adults living in an urban area of the United States (18) . However, dietary data were not available, and this study could not confirm lower phosphate intake in the adults with lower FGF23 levels. We now extend the findings of the previous study by examining FGF23 levels, dietary phosphate intake, and fractional excretion of phosphate in three populations of young adults with African ancestry living in environments that differ markedly by level of industrialization: urban United States (Maywood, IL), Mahé, Seychelles (upper middle income economy), and Kumasi, Ghana (lower middle income economy) (19). We hypothesized that adults living in more industrialized environments will have higher phosphate intake and net phosphate absorption as reflected by higher urinary excretion of phosphate and higher FGF23 levels compared with adults living in less industrialized environments.
Materials and Methods

Study population
The source population for this study was the Vitamin D Ancillary Study (VIDA), an associated study of the Modeling the Epidemiological Transition Study (METS). In the METS study, a cohort study of 2500 young adults with African ancestry aged 25-45 years, subjects were enrolled between January 2010 and September 2011. VIDA extended the METS study by using the framework of ecological contrasts to investigate vitamin D and bone health. The design and recruitment procedures for this study have been described previously (20) . Participants were enrolled in each of five study sites: Maywood, Illinois; Kingston, Jamaica; Kumasi, Ghana; Cape Town, South Africa; and Mahé Island, Seychelles. FGF23 was measured in participants from three sites: Maywood, Illinois (n ϭ 502), Mahé Island; Seychelles (n ϭ 500); and Kumasi, Ghana (n ϭ 500 (21, 22) . We also excluded individuals with an estimated GFR less than 80 mL/min per 1.73 m 2 (none in Maywood, one in Seychelles, and one in Kumasi) based on the Chronic Kidney Disease-Epidemiology Collaboration equation (23) . This left a total of 456, 472, and 468 participants from the United States, Seychelles, and Ghana, respectively, included in the analyses. The METS and VIDA studies were approved by the institutional review boards at all sites, and written content was obtained from all participants in their native language.
Laboratory measurements
Participants fasted for 10 hours prior to the collection of blood samples. Specimens were immediately processed and shipped frozen to the coordinating center in Chicago and maintained in a Ϫ80°C freezer. FGF23 levels were measured in plasma at the University of Miami School of Medicine (Miami, Florida) using an ELISA that uses two antibodies directed against different epitopes within the carboxyl-terminal portion of FGF23 and thus captures both the intact hormone and its carboxyl-terminal fragments (Immutopics) with coefficients of variation of less than 5%. The lower limit of detection was 12 RU/mL. Plasma and urine phosphate were measured via spectrophotometry at the University of Miami School of Medicine, and serum and urine creatinine were measured using nephelometry. Fractional excretion of phosphate was calculated as the ratio of (urine phosphate ϫ plasma creatinine)/(plasma phosphate ϫ urine creatinine) and then multiplied by 100%. High fractional excretion of phosphate was defined as values greater than 20%. Total 25-hydroxyvitamin D was measured using a liquid chromatography-tandem mass spectrometric assay at the University of Washington (Seattle, Washington). The calibration of the assay was verified using the National Institute of Standards and Technology standard reference material SRM 972. Interassay variability was 6.0% at 11.5 ng/mL and 5.6% at 12.3 ng/mL for 25-hydroxyvitamins D2 and D3, respectively.
Demographic and dietary data
Demographic and anthropometric data and basic health history were collected by trained staff using standardized questionnaires in the participants' native language. Dietary intakes were doi: 10.1210/jc. press.endocrine.org/journal/jcemcollect by two 24-hour recalls using the multiple-pass method. All 24-hour recalls were collected by centrally trained interviewers and sent to the Coordinating Center at Loyola University Chicago (Chicago, Illinois) where the data were entered and analyzed using the Nutrient Data System for Research (University of Minneapolis, Minneapolis, Minnesota). The Nutrient Data System for Research was modified to accommodate foods and recipes unique to each site using the current available site-specific nutrient databases and previously collected 24-hour recall data (21) .
Statistical analysis
STATA/IC 13.1 (StataCorp LP) was used to perform all statistical analysis. Summary statistics for key baseline characteristics were compared by site and sex. After stratifying by sex, continuous variables were compared across the three sites using an ANOVA, and categorical variables were compared using the Fisher's exact test. The level of statistical significance was set as P Ͻ .01 to account for multiple comparisons. Scatterplots of FGF23 levels by plasma phosphate, dietary phosphate intake, and fractional excretion of phosphate were examined. Spearman rank correlation coefficients were calculated to quantify the correlation between plasma phosphate, dietary phosphate intake, fractional excretion of phosphate, and FGF23 levels after pooling all three sites. Histograms of variables were examined and FGF23 demonstrated a right skewed distribution. The optimal transformation of FGF23 to normality, as determined by the ladder of powers approach, was a log transformation and the histogram of log transformed FGF23 showed a normal distribution.
To examine differences in FGF23 levels across sites, unadjusted and adjusted geometric mean values of log-transformed FGF23 levels were calculated for each site. SEs were calculated using the ␦-method (24), and adjusted geometric mean values were adjusted for age, sex, and body mass index (BMI). Separate standardized linear regression models were constructed to examine the association between log-transformed FGF23 as the dependent variable and plasma phosphate levels, dietary phosphate intake, and the fractional excretion of phosphate as independent variables with adjustment for age, sex, BMI, and total 25-hydroxyvitamin D levels in the pooled sample. Interaction terms were fitted in the fully adjusted models to explore effect modification by sex. Standardized regression coefficients were obtained by standardizing ([value Ϫ mean]/SD) values for plasma phosphate, dietary phosphate intake, and fractional excretion of phosphate. These coefficients resemble partial correlation coefficients and can be interpreted as the correlation between a given variable after accounting for the effect of other variables in the model. Furthermore, the standardized regression coefficient associated with a variable represents the anticipated change in SD units of the dependent variable for every SD change in the variable of interest. Table 1 shows the characteristics of the study participants. Mean BMI and both systolic and diastolic blood pressures were highest among men and women in Maywood compared with men and women in Seychelles or Ghana. The distribution of 25-hydroxyvitamin D levels has previously been described (25) , and overall, total 25-hydroxyvitamin D levels were significantly lower among men and women in the United States compared with men and women in Seychelles or Ghana. Plasma phosphate levels were highest in both men and women in Ghana , respectively. The fractional excretion of phosphate was significantly lower among men and women in Ghana compared with US men and women, respectively, but no significant difference in the fractional excretion of phosphate was noted between the United States and Ghana for both men and women. Figure 2 shows the scatterplots of FGF23 levels by plasma phosphate levels, dietary phosphate intake, and by the fractional excretion of phosphate, and Table 3 shows the Spearman rank correlation coefficients for FGF23 levels and plasma phosphate levels, dietary phosphate intake, and the fractional excretion of phosphate. FGF23 levels were significantly and positively correlated with dietary phosphate intake (r ϭ 0.11; P Ͻ .001, and the fractional excretion of phosphate (r ϭ 0.13; P Ͻ .001) but not with plasma phosphate levels (Ϫ0.001; P ϭ .8). Dietary phosphate intake was significantly and positively associated with the fractional excretion of phosphate (r ϭ 0.23; P Ͻ .001). Table  4 shows the results of the standardized linear regression models. Both dietary phosphate intake and the fractional excretion of phosphate were significantly associated with FGF23 levels with adjustment for age, sex, BMI, and total 25-hydroxyvitamin D levels but not plasma phosphate levels. However, after adjustment for site, both dietary phosphate intake and fractional excretion of phosphate were no longer associated with FGF23 levels.
Results
Discussion
We used data from young adults living in three different environments to examine whether FGF23 levels differ across populations with varying levels of economic transition and industrialization. In this ecological analysis, we found significantly higher levels of phosphate intake, fractional excretion of phosphate, and FGF23 levels in the United States compared with Ghana. Even after adjusting for demographics, FGF23 levels remained significantly higher in the United States compared with Seychelles or Ghana. Whereas no significant association was noted between FGF23 and plasma phosphate levels, FGF23 was significantly and positively correlated with phosphate intake and the fractional excretion of phosphate in the pooled sample. We also found that dietary phosphate intake was significantly and positively associated with the fractional excretion of phosphate. The results of this study are supported by our previous study demonstrating higher urinary phosphate excretion and FGF23 levels in a small sample of adults living in the urban United States compared with adults living in a rural village in Nigeria (18) , suggesting a gradient of FGF23 levels across the economic transition. This previous pilot study did not have information on dietary factors and included only two sites with a small number of individuals in each site. The present study includes study populations from three sites across a gradient of industrialization and demonstrates that dietary phosphate intake differs significantly by the level of industrialization. FGF23 levels in the present study were no longer significant after adjusting for site, but this was likely due to the low variability in both phosphate intake and urinary phosphate excretion within each site. The pooling of three sites with marked differences in FGF23 levels and net gastrointestinal phosphate absorption likely facilitated discernment of their association. The correlation between FGF23 levels and dietary phosphate intake was fairly weak, consistent with previous studies, (8, 12, 26) , and this weak association may be due to difficulties in accurately assessing dietary phosphate intake (16) . We also noted higher FGF23 levels in women compared with men across all sites, whereas plasma phosphate levels, within each site, were similar between men and women. Higher FGF23 values in young women vs young men may be due to the effects of estradiol on FGF23 production. Both FGF23 mRNA and FGF23 serum levels increase in ovariectomized rats after treat- ment with 17␤-estradiol (27) . In addition, menopause, a state of low estradiol levels, is associated with lower urinary phosphate excretion (28) , with estradiol treatment for menopause increasing urinary phosphate excretion (13) . Higher levels of FGF23 among women may have also been a function of lower iron stores, especially because the majority of these women were likely premenopausal (21, 22) .
Populations living in highly industrialized societies may have higher population mean levels of FGF23 compared with populations living in less industrialized societies due to differences in diet. Diets characterized by a high intake of meats and processed foods preserved with phosphate additives, common in industrialized societies, will have higher phosphate content compared with diets high in vegetable protein and low in processed foods. Diets consistently high in phosphate, especially inorganic phosphate, will lead to compensatory increases in FGF23 levels to maintain serum phosphate levels within a tight range Elevated circulating levels of both phosphate and FGF23 levels have been associated with an increased risk for adverse cardiovascular outcomes including cardiac hypertrophy, atrial fibrillation, stroke, and mortality (29 -33) . For example, in a community health study of adults older than age 40 years living in Manhattan, New York, a plasma FGF23 value greater than 90 RU/mL was associated with a 50% higher risk for a stroke over a 12-year follow-up period after adjustment for GFR, demographic factors, and vascular risk factors (33) . Although it remains premature to suggest a safe upper level of phosphate intake, increasing transparency regarding the phosphate content of food will provide consumers more knowledge regarding their individual phosphate intake. Currently the US Food and Drug Administration regulations do not require food producers to provide phosphate content on nutrition labels (34) .
The strengths of this study include the use of three large populations of young adults living in environments with different diets and access to processed foods. The collection of demographic, anthropometric, and laboratory data were completed using standardized survey instruments and collection procedures. The limitations of the study include the use of spot urine samples to calculate the fractional excretion of phosphate because timed urine collections may provide a more accurate and comprehensive description of phosphate absorption and excretion. The misclassification of urinary phosphate excretion was likely nondifferential and would have biased our findings toward the null. Because food manufacturers are currently not required to report the amount of phosphate added to foods (34), total phosphate intake was likely underestimated, especially within the US site. All participants were instructed to fast for 10 hours prior to the clinic visit when blood samples were collected, and standard protocols were used for blood and urine collection across all study sites. However, it is possible that some variance in plasma press.endocrine.org/journal/jcemphosphate levels was due to differences in the time of sample collection, given the known circadian changes in circulating phosphate levels (35) . This study also used an assay that measures the C-terminal fragment of FGF23, which may be influenced by iron deficiency, and to address this, we excluded individuals with FGF23 values greater than 200 RU/mL. Most study participants with FGF23 levels greater than 200 RU/mL were US women. We did not have information on serum iron or ferritin levels and cannot confirm that participants with FGF23 values greater than 200 RU/mL had low serum iron levels.
Whereas the results with the C-terminal fragment and intact FGF23 assays have yielded qualitatively similar associations in most settings (36) , the findings of this study should be confirmed using an assay that measures intact FGF23 levels.
Conclusion
This study suggests that the distribution of FGF23 levels in a given population may be influenced by the level of industrialization, likely due to differences in access to foods preserved with phosphate additives. Because higher FGF23 levels are associated with a heightened risk for cardiovascular disease, future studies should further explore the association between chronic dietary phosphate intake, FGF-23 levels, and their association with health outcomes.
